Treatment of chronic hepatitis delta with pegylated interferon-α2b
Article first published online: 28 JUN 2006
Volume 26, Issue 7, pages 805–810, September 2006
How to Cite
Erhardt, A., Gerlich, W., Starke, C., Wend, U., Donner, A., Sagir, A., Heintges, T. and Häussinger, D. (2006), Treatment of chronic hepatitis delta with pegylated interferon-α2b. Liver International, 26: 805–810. doi: 10.1111/j.1478-3231.2006.01279.x
- Issue published online: 28 JUN 2006
- Article first published online: 28 JUN 2006
- Received 18 January 2006,accepted 19 March 2006
Abstract: Background/Aims: Chronic hepatitis D is difficult to treat. The present pilot study investigated the efficacy and tolerability of pegylated (PEG)-interferon (IFN)-α2b in chronic hepatitis D.
Patients and Methods: Twelve patients with chronic hepatitis D were prospectively treated with 1.5 μg/kg PEG-IFN-α2b for 48 weeks and followed for 24 weeks. Sustained response (SR) was defined as undetectable hepatitis delta virus (HDV) RNA by reverse transcriptase-polymerase chain reaction and normalization of alanine aminotransferase (ALT) at 6 months after treatment. Investigations included HDV RNA kinetics, determination of hepatitis B virus (HBV) and HDV genotypes and histological evaluation.
Results: An SR was achieved in two out of 12 of patients (17%). The negative predictive value of a less than 3 log HDV RNA decrease at month 6 was 100%. The positive predictive value of a more than 3 log HDV RNA decrease at month 6 was 67%. A marked ALT reduction at the end of treatment was observed in responders and nonresponders. Ishak histological score was comparable at baseline and significantly improved in responders compared with nonresponders at the end of follow-up (13.5 vs. 8.0; P<0.02).
Conclusion: The present study indicates that PEG-IFN-α2b is a promising treatment option in chronic hepatitis D. Nonresponders could be identified by a less than 3 log decrease of HDV RNA at 6 months of treatment.